Alex Brill Talks Trade Disruption Due to Suez Canal Blockage on i24 News
Alex Brill joined i24 News’ Natasha Kirtchuk on “Global Eye” to discuss the cargo ship blocking the Suez Canal, and the trade impacts felt around the world.
U.S. Spending and Tax Policy After the COVID Recessions: Political Economy Podcast
Alex Brill recently joined James Pethokoukis on AEI’s Political Economy Podcast to discuss the potential economic impacts of spending initiatives in the wake of the COVID-19 pandemic.
The Tax Benefits of Parenthood: A History and Analysis of Current Proposals
Since 1917, tax filers with children have received ever-increasing federal income tax benefits. The tax benefits include deductions for each child or other dependent, lower tax brackets for head-of household filers compared to single filers with similar incomes, and tax credits for children and childcare expenses.
Almost-Speaker McCarthy
Four years ago, many commentators lamented that Hillary Clinton fell short of winning the Electoral College by less than 80,000 votes. “You Could Fit All the Voters Who Cost Clinton the Election in a Mid-Sized Football Stadium,” read a headline in Vanity Fair. Now, it is not just Hillary Clinton that lost by a hair.
MGA’s Alex Brill on CNBC’s Squawk Box
MGA’s Alex Brill on CNBC’s Squawk Box
On this episode of ‘Squawk Box,’ Brill discusses Bill Gate’s reaction to Senator Elizabeth Warren’s proposed wealth tax, as well as the capital gains tax.
The Economics of Biologic Drugs
The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014.
Debate Over Whether Biologics Constitute Natural Monopolies Continues
“Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first wrote in April that biosimilar competition is an economically inefficient way to achieve the goal of lower prices; the biosimilar environment is different than the one that exists in the generic marketplace for small-molecule drugs. These authors said, instead, that biosimilars are natural monopolies and as such need price regulation in order for them to succeed and for prices to come down.”